KARO BIO AB overview

Karo Pharma Aktiebolag's application for de-listing has been approved PR Newswire STOCKHOLM, Nov. 11, 2022 STOCKHOLM , Nov. 11, 2022 /PRNewswire/ -- Karo Pharma Aktiebolag's (" Karo Pharma " or the " Company ") application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma's share on Nasdaq First North Growth Market will be 24 November 2022 . As previously announced, Karo Pharma has applied for de-listing of the Company's shares from Nasdaq First North Growth...

Karo Pharma Aktiebolag applies for de-listing PR Newswire STOCKHOLM, Nov. 10, 2022 STOCKHOLM , Nov. 10, 2022 /PRNewswire/ -- The Board of Directors of Karo Pharma Aktiebolag (" Karo Pharma " or the " Company ") has resolved to apply for de-listing of the Company's shares from Nasdaq First North Growth Market following that Karo Intressenter AB [1] (" Karo Intressenter ") controls more than 90 percent of the shares in Karo Pharma and has initiated compulsory redemption of the remaining shares in...

Karo Intressenter AB initiates compulsory redemption PR Newswire STOCKHOLM, Sept. 26, 2022 STOCKHOLM , Sept. 26, 2022 /PRNewswire/ -- Karo Intressenter AB [1] (" Karo Intressenter ") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (" Karo Pharma " or the " Company ") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the " Offer "). On 19 September 2022 , Karo Intressenter announced the outcome of the Offer, that...

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion PR Newswire STOCKHOLM, Aug. 26, 2022 STOCKHOLM , Aug. 26, 2022 /PRNewswire/ -- Background On 16 August 2022 , Karo Intressenter AB [1] (" Karo Intressenter ") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (" Karo Pharma ") to acquire the shares in Karo Pharma not already held by Karo Intressenter (the " Offer ") at a price of SEK 60 per share (the "...

Comment from Karo Pharma Aktiebolag's board of directors regarding the public offer from Karo Intressenter AB PR Newswire STOCKHOLM, Aug. 16, 2022 STOCKHOLM , Aug. 16, 2022 /PRNewswire/ -- Today, on 16 August 2022 , Karo Intressenter AB [1] (" Karo Intressenter ") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (" Karo Pharma ") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the " Offer "). For further...

Karo Pharma: Interim report H1 2022 PR Newswire HUDDINGE, Sweden, July 21, 2022 HUDDINGE, Sweden , July 21, 2022 /PRNewswire/ -- January – June Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the period. The organic growth 1 during the period was +6%. The currency impact was +3% while the acquisitions of the Sylphar Group and E45 ® brand portfolio from Reckitt generated growth of +26%. EBIT (Operating Profit) amounted to MSEK 3.8 (159.1), corresponding to...

Karo Pharma's rights issue fully subscribed PR Newswire HUDDINGE, Sweden, April 19, 2022 HUDDINGE, Sweden , April 19, 2022 /PRNewswire/ -- Not for release, publication or distribution, directly or indirectly, in or into Australia , Hong Kong , Japan , Canada , New Zealand , South Africa , Switzerland , Singapore , the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an...

Karo Pharma publishes the 2021 annual report PR Newswire HUDDINGE, Sweden, April 12, 2022 HUDDINGE, Sweden , April 12, 2022 /PRNewswire/ -- Today, on 12 April 2022 , Karo Pharma is publishing its annual report for 2021 on the company's website, www.karopharma.com . For further information, please contact: Lisa Westerdahl , Head of Corporate Communication, 073-329 70 04, [email protected] Jon Johnsson , CFO, 073-507 88 61, [email protected] The Annual Report is published in...